The researchers found that DHB can influence the behavior of CD8+ T cells, immune cells responsible for identifying and destroying infected or malignant cells. These cells are not fully differentiated into short-lived effector cells; instead, they retain the capacity for self-renewal and can generate new waves of tumor-directed immune cells. In practical terms, this means that a greater proportion of the administered material reached the circulation and remained available to influence immune cells. Subject of Research: Gut microbial metabolite DHB, CD8+ T-cell stemness, cancer immunotherapy, and oral nanomedicine. Keywords: DHB; 3,4-dihydroxybenzoic acid; gut microbiome; CD8+ T cells; T-cell stemness; cancer immunotherapy; immune checkpoint inhibitors; nanomedicine; oral drug delivery; Akt-mTORC1-Myc pathway; glycolysis; tumor immunity.